Sage Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
Biogen Inc. and Biogen MA Inc. have fully divested their entire beneficial ownership in Sage Therapeutics, Inc., selling all 6,241,473 shares at $8.53 per share.
Biogen Inc. plans to tender its 10% stake in Sage Therapeutics, Inc. following the rejection of its acquisition proposal and Sage's subsequent merger agreement with Supernus Pharmaceuticals, Inc.
SCHEDULE 13D: Biogen Proposes Cash Acquisition of Sage Therapeutics at $7.22 Per Share, Building on Existing Collaboration
Biogen Inc. and its subsidiary Biogen MA Inc. have submitted a non-binding proposal to acquire all outstanding shares of Sage Therapeutics, Inc. not currently owned by them for $7.22 per share in cash.